In April 2025, shares of Eli Lilly & Co. $LLY experienced their most significant single-day decline since October of the previous year. This sharp drop followed the announcement by CVS Health Corp. $CVS that it would exclude the popular weight-loss drug Zepbound from its list of preferred medications. The decision raised concerns among investors as it makes Wegovy, a competitor drug produced by Eli Lilly, more accessible to patients.